IVD China last week: Roche, Sysmex and Beijing QuantoBio, Dirui, Livzon, Singlera Genomics and Pure Medical

Roche Diagnostics’ VENTANA MMR RxDx Panel CDx Approved in China

Roche Diagnostics’ VENTANA MMR RxDx Panel companion diagnostic (CDx) reagent has officially obtained approval of NMPA. As China’s first CDx product designed to assist in identifying solid tumor patients eligible for pembrolizumab treatment by assessing DNA mismatch repair (MMR) status, it fills a critical gap in the field. This approval marks a new phase in companion diagnostics for immuno-oncology in Chinese solid tumor patients, and will enabling more patients to access highly effective, accessible, and personalized diagnosis and treatment plans.

Sysmex Signs Strategic Cooperation Agreement with Beijing QuantoBio Biotechnology to Deepen Its Footprint in the Clinical Flow Cytometry Market

Leading global in vitro diagnostic company Sysmex and China's leading clinical flow cytometry enterprise Beijing QuantoBio Biotechnology officially signed a strategic cooperation agreement. This collaboration will achieve strategic upgrading across multiple dimensions including technical synergy, market expansion, and product innovation. This cooperation sets an innovative paradigm for the collaborative development of the IVD industry and even the healthcare sector.

Leading Bangladeshi Healthcare Group Popular Diagnostic Centre Visited Dirui Medical and Signed Strategic Cooperation Agreement

On December 25, 2025, a delegation of 30 representatives from Popular Diagnostic Centre Ltd., a leading private diagnostic chain group in Bangladesh, paid a visit to Dirui Medical. PDC maintains its top position among private diagnostic chain laboratories nationwide, with a network covering over 23 branches and 41 medical facilities across Bangladesh. The two parties conducted in-depth discussions on topics such as technical adaptation, product optimization, and cooperation model innovation, and jointly signed a strategic cooperation agreement at the conclusion of the meeting.

Livzon to Acquire 64.81% Equity in Vietnamese Listed Company for RMB 1.587 Billion, Expanding Southeast Asian IVD Market Presence

On December 30, 2025, Livzon Group released the "Progress Announcement on the Proposed Public Tender Offer for Equity in Vietnam's IMP Company". LIAN SGP HOLDING PTE. LTD., a wholly owned overseas subsidiary of Livzon Group, plans to acquire a combined 64.81% equity interest in Imexpharm Corporation, a Vietnamese listed company, aiming to tap into the high-growth Southeast Asian IVD market.

As one of Vietnam's leading pharmaceutical companies, IMP holds a prominent position in the local healthcare sector. The total consideration for the proposed transaction is RMB1.587 billion, converted at the central parity rate of the exchange rate on the date of the agreement signing.

Singlera Genomics Enters Strategic Partnership with Cross-Border Medical Device Provider Pure Medical to Bring Innovative Cancer Early Detection Technologies to Western Europe

On December 24, 2025, Singlera Genomics (Shanghai) Ltd and EU-based international healthcare company Pure Medical announced the establishment of a strategic partnership. Under the terms of the agreement, Singlera and Pure Medical will collaborate with local universities, hospital networks, and national healthcare systems to conduct research in Western Europe, and commercially jointly promote products based on the mTitan® and mGuard® technology platforms, including early detection products for colorectal cancer and pancreatic cancer, across multiple European countries.